Skip to main content
Personalized Telemedicine Semaglutide in human proportions

A semaglutide reading list

Appetite biology, the weight result, the cardiovascular record and longer treatment.

Experimental appetite research

The rodent experiments on distributed neural pathways describe changes in food intake and preference without a decrease in energy expenditure. The human starting point is STEP 1 in adults with overweight or obesity without diabetes. These lead into the appetite essay.

The relation between the rodent and human findings is my particular preoccupation. One describes experimental biology in mice and rats; the other reports a human weight outcome. The dedicated safety review belongs beside them because it discusses treatment burdens and the risk–benefit profile in type 2 diabetes.

Cardiovascular populations

SELECT concerns established cardiovascular disease and overweight or obesity without diabetes. SUSTAIN-6 concerns type 2 diabetes at high cardiovascular risk, including its reported eye-complication signal. STEP-HFpEF concerns obesity-related heart failure with preserved ejection fraction, symptoms and physical limitations.

Together these are the main reading for the cardiovascular essay. Their separate populations are part of their interest. Flattening that variety into a single statement about heart health would erase the circumstances that give the results their particular meaning for me.

Treatment duration

The longer on-treatment observation in STEP 5 sits beside STEP 1 in the essay on time. The sustained reduction in weight over 104 weeks gives the duration question a concrete place in the discussion.

I put considerable value on the time spent observing a result. The amount of change and its persistence during treatment each deserve attention. The list below gathers the source titles; each paper comes with its own population, circumstance and outcome.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity ↗
  2. Semaglutide lowers body weight in rodents via distributed neural pathways ↗
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ↗
  4. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ↗
  5. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ↗
  6. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial ↗
  7. Safety of Semaglutide ↗